2,496 reports of this reaction
21.8% of all KETOTIFEN FUMARATE reports
#1 most reported adverse reaction
TREATMENT FAILURE is the #1 most commonly reported adverse reaction for KETOTIFEN FUMARATE, manufactured by Alcon Laboratories, Inc.. There are 2,496 FDA adverse event reports linking KETOTIFEN FUMARATE to TREATMENT FAILURE. This represents approximately 21.8% of all 11,458 adverse event reports for this drug.
Patients taking KETOTIFEN FUMARATE who experience treatment failure should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
TREATMENT FAILURE is a frequently reported adverse event for KETOTIFEN FUMARATE, accounting for a significant proportion of all reports.
In addition to treatment failure, the following adverse reactions have been reported for KETOTIFEN FUMARATE:
The following drugs have also been linked to treatment failure in FDA adverse event reports:
TREATMENT FAILURE has been reported as an adverse event in 2,496 FDA reports for KETOTIFEN FUMARATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
TREATMENT FAILURE accounts for approximately 21.8% of all adverse event reports for KETOTIFEN FUMARATE, making it one of the most commonly reported side effect.
If you experience treatment failure while taking KETOTIFEN FUMARATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.